EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics

Jinliang Liang, Huanyi Liu, Guo Lv, Xiaotong Chen, Zhaoshou Yang, Kunhua Hu, Hongyan Sun

Lipids in Health and Disease · 2025

DOI: 10.1186/s12944-024-02416-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lipids in Health and Disease, 2025. Verfasst von Jinliang Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, the Guangzhou Municipal Institute Enterprise Joint Funding Project, the Science and Technology Program of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical studies have suggested that tirzepatide may also possess hepatoprotective effects; however, the molecular mechanisms underlying this association remain unclear. In our study, we performed biochemical analyses of serum and histopathological examinations of liver tissue in mice. To preliminarily explore the molecular mechanisms of tirzepatide on metabolic dysfunction-associated fatty liver disease (MAFLD), liquid chromatography-mass spectrometry (LC-MS) was employed for comprehensive metabolomic, lipidomic, and proteomic analyses in MAFLD mice fed a high-fat diet (HFD). The results demonstrated that tirzepatide significantly reduced serum levels of alanine transaminase (ALT) and aspartate transaminase (AST), as well as hepatic triglycerides (TG) and total cholesterol (TC), indicating its efficacy in treating MAFLD. Further findings revealed that tirzepatide reduced fatty acid uptake by downregulating Cd36 and Fabp2/4, as well as enhance the mitochondrial-lysosomal function by upregulating Lamp1/2. In addition, tirzepatide promoted cholesterol efflux and reduced cholesterol reabsorption by upregulating the expression of Hnf4a, Abcg5, and Abcg8. These results suggest that tirzepatide exerts its therapeutic effects on MAFLD by reducing fatty acid uptake, promoting cholesterol excretion, and enhancing mitochondrial-lysosomal function, providing a theoretical basis for a comprehensive understanding of tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseFatty LiverAnimalsMiceProteomicsLipidomicsDiet, High-FatMetabolomicsMaleLiverTriglyceridesCholesterolLipid MetabolismAspartate AminotransferasesMice, Inbred C57BLAlanine TransaminaseTirzepatide

Stichwörter der Autor:innen

LipidomicsMetabolic dysfunction-associated fatty liver diseaseMetabolomicsProteomicsTirzepatide

Substanzen

TriglyceridesCholesterolAspartate AminotransferasesAlanine TransaminaseTirzepatide

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • The First Affiliated Hospital, The First School of Clinical Medicine of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, 510080, China.
  • Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. hukunh@mail.sysu.edu.cn.
  • The State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. sunhy@sysucc.org.cn.

Förderung

  • the National Natural Science Foundation of China
  • the Guangzhou Municipal Institute Enterprise Joint Funding Project
  • the Science and Technology Program of Guangzhou

Zitieren

APA

Liang, J., Liu, H., Lv, G., Chen, X., Yang, Z., Hu, K., & Sun, H. (2025). Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics. Lipids in Health and Disease. https://doi.org/10.1186/s12944-024-02416-2

Vancouver

Liang J, Liu H, Lv G, Chen X, Yang Z, Hu K, et al. Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics. Lipids in Health and Disease. 2025. doi:10.1186/s12944-024-02416-2

BibTeX
@article{Liang2025,
  author = {Liang, Jinliang and Liu, Huanyi and Lv, Guo and Chen, Xiaotong and Yang, Zhaoshou and Hu, Kunhua and Sun, Hongyan},
  title = {Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics},
  journal = {Lipids in Health and Disease},
  year = {2025},
  doi = {10.1186/s12944-024-02416-2}
}
Kostenlos starten →